)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
ArriVent BioPharma (AVBP) investor relations material
ArriVent BioPharma Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary10 Nov, 2025
Executive summary
Focused on developing firmonertinib for EGFR-mutant NSCLC, with multiple ongoing clinical trials and recent positive data readouts for uncommon mutations, including PACC and exon 20 insertions; final Phase 1b results showed clinically meaningful progression-free survival and CNS complete responses, supporting advancement to pivotal Phase 3 trials.
Expanded pipeline with new ADC collaborations (Alphamab, Aarvik, Lepu), including FDA IND clearance for ARR-217, a CDH17-targeted ADC, and ongoing Phase 1 study in China and U.S. IND clearance.
Appointment of Brent S. Rice as Chief Commercial Officer, bringing over 25 years of global commercial experience.
No product revenue to date; operations funded by equity offerings and collaborations.
Cash and investments of $305.4 million as of September 30, 2025, expected to fund operations into mid-2027.
Financial highlights
Net loss of $34.98 million for Q3 2025, up from $20.56 million in Q3 2024; net loss of $130.8 million for the nine months ended September 30, 2025, compared to $59.9 million for the same period in 2024.
Research and development expenses rose to $32.17 million in Q3 2025 (from $20.09 million) and $121.2 million for the nine months (from $58.84 million), including a $40 million one-time upfront payment for ARR-217 in-licensing.
General and administrative expenses increased to $6.15 million in Q3 2025 and $17.54 million for the nine months, reflecting higher personnel and professional costs.
Cash, cash equivalents, and marketable securities totaled $305.4 million as of September 30, 2025.
Net cash used in operations was $129.9 million for the nine months ended September 30, 2025, up from $54.1 million in the prior year period.
Outlook and guidance
Cash runway expected to fund operations for at least 12 months from the reporting date and projected into mid-2027.
Enrollment of the first patient in the pivotal ALPACCA Phase 3 study for firmonertinib in EGFR PACC mutant NSCLC expected in Q4 2025.
Top-line pivotal data from the FURVENT Phase 3 trial in EGFR exon 20 insertion mutant NSCLC projected for early 2026.
Anticipates continued increases in R&D and G&A expenses as pipeline advances and headcount grows.
Additional ADC programs expected to progress toward the clinic, expanding the pipeline.
Firmonertinib's CNS benefit for PACC patients
ARR-217's best-in-class potential rationale
Commercial strategy for firmonertinib launch
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next ArriVent BioPharma earnings date
Q4 20253 Mar, 2026
Next ArriVent BioPharma earnings date
Q4 20253 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
ArriVent BioPharma Inc. is a clinical-stage biopharmaceutical company focused on the identification, development, and commercialization of innovative medicines to meet the unmet medical needs of patients with cancers. The company specializes in developing targeted cancer therapies, including for non-small-cell lung cancer (NSCLC) and other solid tumors. A key product in its pipeline is Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage